Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000029414 | SCV000052064 | likely pathogenic | X-linked agammaglobulinemia | 2011-08-18 | criteria provided, single submitter | curation | Converted during submission to Likely pathogenic. |
Labcorp Genetics |
RCV001055502 | SCV001219900 | pathogenic | X-linked agammaglobulinemia with growth hormone deficiency | 2022-10-28 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This sequence change affects an acceptor splice site in intron 8 of the BTK gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BTK are known to be pathogenic (PMID: 15661032, 16862044, 19419768). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with clinical features of X-linked agammaglobulinemia (PMID: 10844531, 19419768; Invitae). ClinVar contains an entry for this variant (Variation ID: 35762). For these reasons, this variant has been classified as Pathogenic. |